Oncology

Filter

Expanding Treatment Horizons: Advancements in Key mCRC Populations

August 2025

The following topics were covered during a symposium at the 2025 European Society for Medical Oncology Gastrointestinal Cancers (ESMO-GI)…

The experience of Biosimilar Medicines in Oncology

This webinar takes a retrospective look at the use of monoclonal antibody biosimilars in the treatment of breast cancer.

EAU23 Highlights: Best treatments for localised disease

Dr Alberto Bossi. During EAU23 in Milan, Dr Alberto Bossi discusses the most recent advances in treatments for localised disease.

EMJ

EAU23 Highlights: Advanced hormone sensitive prostate cancer

Prof. Bernd Schmitz-Dräger. On the third day of EAU23 in Milan, Professor Bernd Schmitz-Dräger presents highlights from the congress in advanced hormone sensitive prostate cancer treatment.

EAU23 Highlights: Screening, early detection and advanced prostate cancer

Professor Peter Hammerer. On the final day of EAU23 in Milan, Professor Peter Hammerer provides updates from the congress on screening, early detection and advanced prostate cancer.

Onco-Fertility Care

With the growing number of young patients who have survived cancer, onco-fertility care has become an essential aspect of cancer disease management. This webinar explores the different aspects involved in onco-fertility care, including fertility risk, prevention strategies, and pregnancy planning.

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Chaired by Prof. Andrea Necchi, this symposium presented by Prof. Rouprêt and Prof. Retz explores the treatment landscape for muscle-invasive urothelial carcinoma, as well as their perspectives on future treatment landscape.

Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine

Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).

A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL

Not able to attend the Expert Roundtable Discussion in Paris? Access the on-demand webcast here. This interactive event features expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Topics include:

Prosigna on demand webinars

Interactive webinar designed for doctors treating breast cancer interested in advancing personalized treatment through molecular gene expression testing.

From Clinical Trial to Real-World Evidence: Everyday Practice with METex14 Inhibitors in NSCLC

This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).

Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment

The 37th Annual European Association of Urology (EAU) Congress 2022 in Amsterdam, the Netherlands, where data from the CLEAR study, a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab combination therapy against sunitinib as first-line treatment in patients with advanced renal cell carcinoma, were presented.

Breaking Through the Firewall: New Therapeutic Strategies to Disrupt Cancer's Operating Systems

This symposium session presented at the ESMO 2022 included presentations exploring different and new aspects of treating patients.

Management of patients with oncogene-driven NSCLC: the shift towards personalized medicine

Management of patients with oncogene-driven NSCLC: the shift towards personalized medicine

Discuss the importance of the implementation of biomarker testing in routine clinical practice and the current and future challenges…

Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future

Navigating the Current Treatment Landscape in Esophageal Cancer with an Eye Toward the Future

Novartis sponsored ESMO 2021 Satellite Symposium: Navigating the Current Treatment Landscape Faculty: Prof Eric…

Second AACR International Meeting: Advances in Malignant Lymphoma

Second AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application held in…

Comprehensive Genomic Profiling (CGP) Enabled by Next-Generation Sequencing Technology

CGP enabled by next-generation sequencing (NGS) technology allows all known biomarkers to be evaluated in a single test.

ESMO 2018 - Congress Highlights

Catch up on this year’s European Society for European Society for Medical Oncology (ESMO) annual congress, with our inside look at the Internationales…

Progress in the treatment of chronic lymphocytic leukaemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…

New trials for cancer patients at Sarah Cannon Research Institute

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK…

EMJ

ASSIST-FL – Primary Outcome: Interview with Prof. Jurczak

In this interview, Professor Wojciech Jurczak presents and discusses the primary results of ASSIST-FL, the confirmatory, PhIII randomised, double blinded…

EMJ

Prof. Marie-Pia d’Ortho Interview

Interview with Prof. Marie-Pia d’Ortho.

Personalised screening for breast cancer care

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Andrew Evans, MRCP, FRCR, from…

EMJ

Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German…

EMJ

Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies

The Oncotype DX® 21-gene Recurrence Score® result stratifies patients with breast cancer into low-, intermediate- and high-risk groups that correspond to…

EMJ

Impact of phase 3 PlanB trial on evidence-based clinical practice for breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German…

EMJ

5-year outcomes from PlanB: Phase 3 trial of 21-gene Recurrence Score® result in breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German…

EMJ

Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German…

Defining factors that can predict neoadjuvant chemotherapy response in breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Andrew Evans, MRCP, FRCR, from the…

Genetically determining susceptibility of breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Douglas Easton, PhD, from the…

Surgical considerations after neoadjuvant treatment for breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Isabel Rubio, MD, PhD, from Hospital…

Individualisation of breast cancer therapy

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Isabel Rubio, MD, PhD, from Hospital…

Opportunities for improved outcomes in breast cancer patients

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from…

2005–2015 global analysis of advanced breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD…

Imaging biomarkers as a predictive tool in breast cancer management

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Andrew Evans, MRCP, FRCR, from the…

Abstracts from the 10th European Breast Cancer Conference

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the…

Checkpoint inhibitors for triple-negative breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from…

Precision medicine for breast cancer

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from…

Highlights of the 10th European Cancer Conference (EBCC-10) by Dr Giuseppe Curigliano

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from…

Themes of the 10th European Breast Cancer Conference (EBCC-10)

At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the…

EMJ

Understanding the unique aspects of immunotherapy for lung cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf…

Immunotherapy for head and neck cancer

At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover…

Improving the treatment of advanced renal cell carcinoma

At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover…

Predictive biomarkers for immunotherapy in non-small cell lung cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf…

EMJ

Next-generation sequencing to guide treatment decision-making

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…

EMJ

Introducing next-generation sequencing into the clinical care of cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…

EMJ

Early versus delayed use of tyrosine kinase inhibitors for thyroid cancer

Recent advances in the biological understanding of thyroid cancer have led to the development of targeted therapies, such as the tyrosine kinase…

EMJ

Updating the treatment algorithm for metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…

EMJ

Changing the treatment landscape of metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…

EMJ

Clinical decision-making for pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

EMJ

The significance of BRCA mutations in pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

EMJ

Treatment of pancreatic cancer: Overview of the continued progress

Pancreatic cancer is a leading cause of cancer-related deaths in developed countries. At the German Cancer Congress 2016, held in Berlin, Germany, from…

EMJ

KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

EMJ

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

EMJ

Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…

EMJ

Immunotherapy for hepatocellular carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS…

EMJ

Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD…

EMJ

Endocrine therapy in pregnant women with breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…

EMJ

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS…

EMJ

Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…

From biologics to biosimilars

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the…

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen…

EMJ

Precision medicine for metastatic breast cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS…

EMJ

Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a…

EMJ

Roles of targeted therapy and immunotherapy for gastrointestinal cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD…

EMJ

ESMO 2015 highlights: Putting ovarian cancer management into perspective

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes…

EMJ

Defining ESMO Clinical Practice Guidelines at ESMO Asia 2015

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Andrés Cervantes, MD…

EMJ

Phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste…

EMJ

Update from CheckMate 057: Nivolumab versus docetaxel in advanced non-squamous NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD…

EMJ

Therapeutic advances in immune checkpoint inhibitors for head and neck cancers

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

EMJ

KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

EMJ

LUX-H&N1: Phase 3 trial of afatinib versus methotrexate for head and neck squamous cell carcinoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from…

EMJ

ESMO Clinical Practice Guidelines: Breast cancer case presentation

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Fatima Cardoso, MD, from…

EMJ

Balancing therapeutics and patient access to new cancer drugs

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…

EMJ

Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD…

EMJ

Olaparib: An opportunity for personalised medicine in BRCA-related ovarian cancer

Recently, there have been numerous advances in the biological understanding of ovarian cancer. At the European Society for Medical Oncology (ESMO) Asia…

EMJ

Optimising sequencing of new treatments for prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…

EMJ

A new definition of genetic counselling for ovarian cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Jonathan A. Ledermann…

EMJ

KEYNOTE-010: Pembrolizumab, anti-PD-1, for advanced NSCLC with PD-L1 expression

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

EMJ

Improving outcomes from advanced prostate cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Karim Fizazi, MD, PhD…

EMJ

Cardio-oncology in multiple myeloma

Ola Landgren, MD, PhD from National Cancer Institute, Bethesda, MD talks about cardio-oncology in multiple myeloma (MM). In this new era of more…

EMJ

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

EMJ

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Roy S. Herbst, MD, PhD…

EMJ

AZD9291, an EGFR-TKI, for T790M-mediated resistance in non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

EMJ

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

EMJ

Oncogene-addicted non-small cell lung cancer

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Pasi A. Jänne, MD, PhD…

EMJ

Quality of life and new therapeutic options for metastatic castration-resistant prostate cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…

EMJ

Learn more about the ESMO Asia 2015 Congress

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress…

EMJ

Delivering the promise of immunotherapy for melanoma

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Peter Hersey, MD, PhD…

EMJ

Q&A Session – Impact of the GreenLight Laser System for Day-Case Surgery

Mr Gordon Muir answers questions from the audience about the effect and impact of the Greenlight laser system for day-case surgery, which took place on…

EMJ

Detailed timelines of cancer development

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Peter Van Loo, PhD, from The Francis Crick Institute, London, UK, discusses the…

EMJ

Lifestyle behaviour and cancer prevention

Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at the 2015 National Cancer…

EMJ

Trends in e-cigarette use in England

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Robert West, PhD, from University College London, London, UK, discusses data…

EMJ

Addressing the rapidly changing and diversifying educational needs of clinicians

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Elaine Vickers, PhD, Founder and Principal Trainer of Science Communicated…

EMJ

Cancer survivorship support in the UK and USA

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rachael Crayton, Oncology Specialist Nurse from Central Manchester NHS Foundation Trust, Manchester, UK, discusses the highlighted key themes from a networking exercise with cancer survivorship programmes in the UK and USA that may be used to enhance these services for patients.

EMJ

Evaluating genomic tests for breast cancer management

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…

EMJ

Translating cancer immunotherapy to the clinic

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Sergio Quezada, PhD, from University College London, London, UK, discusses…

EMJ

Neutropenic sepsis: Medical alert bands in clinical practice

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ruth Hammond, Vascular Access and IV Nurse Practitioner, and Clinical…

EMJ

Effective control of chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting (CINV) remains a concern for many cancer patients. At the United Kingdom Oncology Nursing Society (UKONS) Annual…

EMJ

UKONS: Engaging the cancer nursing community in the UK

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Henry, President Elect of the UKONS, and Teaching Fellow at the…

EMJ

Myeloma education today

Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual…

EMJ

Out-of-hours support for cancer patients with a modified UKONS telephone triage tool

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal…

EMJ

Tenovus Cancer Care ‘Sing with Us’ choirs

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care…

EMJ

UKONS: Bringing the nursing community together

Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of the United Kingdom Oncology…

EMJ

Healthy lifestyle choices for patients with cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS…

EMJ

Drug development for metastatic castration-resistant prostate cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer…

EMJ

Opportunities and challenges in immuno-oncology

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK…

EMJ

Defining patient safety at UKONS Annual Conference 2015

Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery…

EMJ

Motivational interviewing in healthcare

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching…

EMJ

Prevention and treatment of chemotherapy-induced nausea and vomiting

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust…

EMJ

ManVan: Mobile cancer support for prostate, testicular and penile cancer

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care…

EMJ

Evaluating the experience of surviving at least five years after a prostate cancer diagnosis

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Natalie Doyle, MSc, RGN, Nurse Consultant at The Royal Marsden NHS…

EMJ

Improving adherence to oral therapies in clinical practice

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Cheryl Vidall, Head of Nursing and Governance at Alcura UK Limited, Alton…

EMJ

Telephone assessment service for patients receiving ipilimumab for metastatic melanoma

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Joanne Upton, Skin Cancer Advanced Nurse Practitioner at The Clatterbridge…

EMJ

Integrating psychological support and physical activity interventions in cancer care

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire…

EMJ

Improving survivorship services in haemato-oncology

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western Hospital…

EMJ

Optimising the assessment of sexuality in oncology

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University…

EMJ

A new model of care for lung cancer patients

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of…

EMJ

Developing a self-management programme to support prostate and testicular cancer survivors

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management needs…

EMJ

Defining the elements of the acute oncology nursing role

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal…

EMJ

Chemotherapy-induced nausea and vomiting – a nurse’s perspective

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of Warwick…

EMJ

Physical activity, obesity and cancer

Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There is now an increasingly large…

EMJ

The use of supplements to complement a healthy and balanced diet for prostate cancer patients

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects of Pomi-T on prostate-specific…

EMJ

Strategies to cope with cancer therapy side-effects

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert…

EMJ

The importance of a healthy and balanced diet for cancer patients

Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas suggests that cancer…

EMJ

Addressing patient safety at the UKONS Annual Conference 2015

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom and beyond…

EMJ

Molecular drivers of metastatic disease in breast cancer

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that genetic…

EMJ

Clinical implications of malnourishment in cancer care

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…

EMJ

Nivolumab and cabozantinib versus standard of care in renal cell carcinoma

Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported…

EMJ

Overcoming acquired resistance to targeted therapies in lung cancer

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that…

EMJ

The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells

At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study…

The impact of the Oncotype DX® Breast Cancer Assay on the patient treatment journey

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…

ASPIRE-PCa: Prospective, global observational study of men with late-stage prostate cancer

At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa…

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a…

Biomarker-driven therapies for triple-negative breast cancer

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups…

EMJ

Improving access to innovation in cancer care in Europe

At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology…

Changing the standard of care in previously treated metastatic renal cell carcinoma

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials…

POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy…

Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma

At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia…

AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer

At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris…

Deciding which of the available genomic tests to use

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in…

Progress in the treatment of BRAF-mutant melanoma

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the…

BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single…

BELIEF: Phase 2 trial of erlotinib and bevacizumab in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer…

MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma

At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety…

Involving patients in the use of their data

Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis…

2015 NCRI Cancer Conference highlights and new NCRI initiatives

Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference…

EMJ

Epigenetic targets in cancer

Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer…

EMJ

Breast Cancer Now: aiming to prevent death from breast cancer by 2050

Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that resulted from the combination of…

EMJ

Investigating the genomic landscape of brain tumours using metabolic imaging

Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he described a new…

EMJ

Systematic assessment of patient and carer needs in the oncology clinical and GP surgery

Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, that focuses on the…

EMJ

How many cancers can we prevent through dietary modifications?

Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. In his talk he discusses…

EMJ

Molecular testing for early cancer diagnosis: ready for prime time

Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, focusing…

EMJ

The origins of CDK by Tim Hunt

Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse and Leland Hartwell…

EMJ

Chemoprevention in breast cancer

Jack Cuzick, PhD, FMedSci, FRCP(hon), of the Queen Mary University of London, UK gives an overview of the session ‘Prevention is better than cure’…

EMJ

Tumour: stroma interactions

In the session ” Tumour: stroma interactions” presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, the importance of…

EMJ

Genomics England: 100,000 Genomes Project

Clare Turnbull, MD, PhD, gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where the Genomics…

EMJ

Reducing prostate cancer progression and mortality: what patients can do to reduce risk

Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how…

EMJ

Helping healthcare professionals initiate conversations about physical activity

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is implementing…

EMJ

Keeping active with Macmillan Cancer Support

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer Support initiative aimed…

EMJ

Physical activity – the panacea?

Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity – the panacea?” at the 2015 National Cancer Research Institute…

EMJ

The development of genomic tests and how validation affects their use in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…

EMJ

2015 NCRI Cancer Conference: Francis Crick Institute scientists

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered…

EMJ

Clonal evolution in colorectal cancer

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Alberto Bardelli, PhD talks about clonal evolution in colorectal cancer. He also…

EMJ

Update on CheckMate 067, an advanced melanoma clinical trial

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab…

EMJ

Physical activity levels and barriers to exercise referral among patients with cancer

Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the…

EMJ

2015 NCRI Cancer Conference: Featured sessions

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…

EMJ

2015 NCRI Cancer Conference: The highlights

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the…

EMJ

Current status and future prospective of Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…

EMJ

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…

EMJ

Immunotherapy: Targeting tumour heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

New approaches to molecular cancer therapeutics

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

The Patient Reported Opinions about Clinical Tolerability (PROACT)

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient…

EMJ

EURECCA international comparison of treatment patterns for non-metastatic breast cancer

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK…

EMJ

Results from the ETOP Lungscape Project: Multiplex mutation testing in NSCLC

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the…

EMJ

The causes and consequences of tumour evolution and heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

Patient-centered partnership improve access to optimal standards of cancer care in Europe

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40…

EMJ

ECC 2015: Press programme with updates on ‘Europe of Disparities in Cancer’

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queen’s University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College…

EMJ

The discovery of new biomarkers for predicting outcomes in breast cancer

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to…

EMJ

First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in…

EMJ

Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC

At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis…

EMJ

ECC 2015: News briefing chaired by Prof Peter Naredi

At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a news briefing with…

EMJ

Phase 2 trial of TAK-385, an oral GnRH antagonist, in prostate cancer

At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim…

EMJ

ECC 2015: Cancer healthcare inequalities between and within countries in Europe

There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest…

EMJ

TAILORx: Prospective phase 3 trial validating a 21-gene expression assay in breast cancer

At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk…

EMJ

ECC 2015: Challenging the European disparities in cancer care

European Cancer Patient Coalition (ECPC), the largest European cancer patients’ umbrella organisation, presented the paper, ‘Europe of Disparities in…

EMJ

ECC 2015: Hormonal therapy may prevent ovarian failure and preserve fertility in breast cancer

A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without…

EMJ

Clinical access to genomic information in Europe

Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD…

EMJ

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry…

EMJ

Phase 1b trial of avelumab in advanced gastric or gastroesophageal junction cancer

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b…

EMJ

ECC 2015: Post-diagnosis aspirin improves survival in gastrointestinal cancers

Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall…

EMJ

ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…

EMJ

ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…

EMJ

ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours

RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US…

EMJ

ECC 2015: Launch of the European Society for Paediatric Oncology (SIOPE) strategic plan

The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field…

EMJ

ECC 2015: News briefing chaired by Prof Martine Piccart

At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…

EMJ

ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…

EMJ

ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe

Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…

EMJ

ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer

METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.

EMJ

The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay

The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…

EMJ

TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…

EMJ

Assessing the eligibility of a breast cancer patient for genomic testing

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…

EMJ

Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Experience of the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…

EMJ

Genomic testing for breast cancer in the neoadjuvant setting

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…

EMJ

Introducing the Oncotype DX® Breast Cancer Assay and its impact in clinical practice

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…

EMJ

The use of Ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some…

EMJ

Introducing the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…

EMJ

Refining the therapeutic approach for breast cancer through genomic profiling

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses…

EMJ

Considerations when selecting a genomic test to use in specific breast cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center…

EMJ

Genomic profiling for defining luminal subtypes

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…

EMJ

Using genomic testing to access the suitability of breast cancer patients for chemotherapy

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the…

EMJ

Registry evaluating the impact of genomic testing on treatment of prostate cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

CancerLinQ: ASCO’s initiative to improve patient care through big data

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE…

EMJ

ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen…

EMJ

An update on the treatment of chronic lymphocytic leukaemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing…

EMJ

HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY…

EMJ

IMAAGEN: Phase 2 trial of abiraterone acetate for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides…

EMJ

CheckMate 067: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…

EMJ

The evolving role of chemotherapy for the management of advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

EMJ

Daratumumab for heavily pretreated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta…

EMJ

Current clinical perspectives on targeted therapy and immunotherapy for melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France…

EMJ

ENDEAVOR: Phase 3 trial comparing carfilzomib versus bortezomib in relapsed multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the…

EMJ

Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…

EMJ

Frontline and relapsed treatment of follicular lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…

EMJ

The Conquer Cancer Foundation of the American Society of Clinical Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center…

EMJ

Evaluating sustained adherence to ibrutinib in previously treated CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success…

EMJ

Therapy for newly diagnosed patients with mantle cell lymphoma

At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new…

EMJ

Introducing biomarkers for the management of patients with prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center…

EMJ

CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides…

EMJ

Developing targeted therapies for melanoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney…

EMJ

Predicting late recurrence of breast cancer

At the 14th St. Gallen International Breast Cancer Conference 2015, Eleftherios P. Mamounas, MD, of University of Florida Health Cancer Center-Orlando…

EMJ

The management of breast cancer in the Japanese population

At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that there are still only…

EMJ

Borealis-1™: Phase 2 trial of gemcitabine/cisplatin plus apatorsen in advanced bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA…

EMJ

PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2…

EMJ

Emerging immunotherapies for kidney cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK…

EMJ

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France…

EMJ

Phase 1b trial of idelalisib in combination with chemoimmunotherapy for relapsed/refractory CLL

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that…

EMJ

PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC…

EMJ

Immune responses and clinical outcomes in STAND trial of sipuleucel-T and ADT in prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses…

EMJ

ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

EMJ

Phase 2 trial of brentuximab vedotin plus AVD for limited-stage Hodgkin lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center…

EMJ

Towards precision medicine in cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 2015–2016 term, Julie M. Vose, MD, MBA, FASCO…

EMJ

Immunotherapy and targeted therapies in melanoma at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews…

EMJ

Focus on geriatric oncology at ASCO 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current…

EMJ

PFS and correlative biomarker analysis from the phase 3 coBRIM study

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale…

EMJ

Individualising therapy in older patients with breast cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, discusses…

Loading posts...

« Previous 1 … 32 33 34 35 36 … 44 Next »